...
grfs-img

Grifols SA ADR, Common Stock

GRFS

NSQ

$7.68

+$0.17

(2.26%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.13B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
35
Volume info-icon
This is the total number of shares traded during the most recent trading day.
790.25K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.69
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.3 L
$12.15 H
$7.68

About Grifols SA ADR, Common Stock

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGRFSSectorS&P500
1-Week Return0.79%-0.94%-2.6%
1-Month Return-10.7%-5.08%-1.08%
3-Month Return-12.73%-10.62%3.45%
6-Month Return6.82%-6.18%8.57%
1-Year Return-25.65%1.98%24.3%
3-Year Return-31.37%-0.93%25.58%
5-Year Return-67.07%33.84%84.07%
10-Year Return-54.73%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue5.10B5.34B4.93B6.06B6.59B[{"date":"2019-12-31","value":77.35,"profit":true},{"date":"2020-12-31","value":81.01,"profit":true},{"date":"2021-12-31","value":74.84,"profit":true},{"date":"2022-12-31","value":91.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue2.76B3.08B2.97B3.83B4.27B[{"date":"2019-12-31","value":64.59,"profit":true},{"date":"2020-12-31","value":72.26,"profit":true},{"date":"2021-12-31","value":69.58,"profit":true},{"date":"2022-12-31","value":89.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit2.34B2.26B1.96B2.23B2.32B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.32,"profit":true},{"date":"2021-12-31","value":83.83,"profit":true},{"date":"2022-12-31","value":95.31,"profit":true},{"date":"2023-12-31","value":99.21,"profit":true}]
Gross Margin45.92%42.23%39.78%36.80%35.24%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.97,"profit":true},{"date":"2021-12-31","value":86.64,"profit":true},{"date":"2022-12-31","value":80.14,"profit":true},{"date":"2023-12-31","value":76.73,"profit":true}]
Operating Expenses1.22B1.28B1.40B1.53B1.58B[{"date":"2019-12-31","value":76.91,"profit":true},{"date":"2020-12-31","value":80.76,"profit":true},{"date":"2021-12-31","value":88.35,"profit":true},{"date":"2022-12-31","value":96.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income1.13B996.13M595.06M805.68M737.92M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.05,"profit":true},{"date":"2021-12-31","value":52.6,"profit":true},{"date":"2022-12-31","value":71.21,"profit":true},{"date":"2023-12-31","value":65.22,"profit":true}]
Total Non-Operating Income/Expense(543.03M)(359.12M)(511.05M)(907.09M)(1.09B)[{"date":"2019-12-31","value":-54303000000,"profit":false},{"date":"2020-12-31","value":-35912100000,"profit":false},{"date":"2021-12-31","value":-51105400000,"profit":false},{"date":"2022-12-31","value":-90708800000,"profit":false},{"date":"2023-12-31","value":-108803400000,"profit":false}]
Pre-Tax Income817.10M878.63M350.45M361.26M224.02M[{"date":"2019-12-31","value":93,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":39.89,"profit":true},{"date":"2022-12-31","value":41.12,"profit":true},{"date":"2023-12-31","value":25.5,"profit":true}]
Income Taxes168.46M169.64M85.13M90.11M43.35M[{"date":"2019-12-31","value":99.3,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":50.18,"profit":true},{"date":"2022-12-31","value":53.12,"profit":true},{"date":"2023-12-31","value":25.55,"profit":true}]
Income After Taxes648.64M708.99M265.33M271.15M180.67M[{"date":"2019-12-31","value":91.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.42,"profit":true},{"date":"2022-12-31","value":38.24,"profit":true},{"date":"2023-12-31","value":25.48,"profit":true}]
Income From Continuous Operations648.64M708.99M265.33M271.15M138.29M[{"date":"2019-12-31","value":91.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.42,"profit":true},{"date":"2022-12-31","value":38.24,"profit":true},{"date":"2023-12-31","value":19.51,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income625.15M618.55M265.33M208.28M59.31M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.94,"profit":true},{"date":"2021-12-31","value":42.44,"profit":true},{"date":"2022-12-31","value":33.32,"profit":true},{"date":"2023-12-31","value":9.49,"profit":true}]
EPS (Diluted)1.181.200.870.200.46[{"date":"2019-12-31","value":98.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.28,"profit":true},{"date":"2022-12-31","value":16.34,"profit":true},{"date":"2023-12-31","value":38.23,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GRFS
Cash Ratio 0.34
Current Ratio 2.26
Quick Ratio 0.79

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GRFS
ROA (LTM) 2.87%
ROE (LTM) 2.71%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GRFS
Debt Ratio Lower is generally better. Negative is bad. 0.61
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.26

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GRFS
Trailing PE 35.00
Forward PE 8.35
P/S (TTM) 0.85
P/B 0.91
Price/FCF 33
EV/R 2.02
EV/Ebitda 9.64
PEG 0.23

FAQs

What is Grifols SA ADR share price today?

Grifols SA ADR (GRFS) share price today is $7.68

Can Indians buy Grifols SA ADR shares?

Yes, Indians can buy shares of Grifols SA ADR (GRFS) on Vested. To buy Grifols SA ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GRFS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Grifols SA ADR be purchased?

Yes, you can purchase fractional shares of Grifols SA ADR (GRFS) via the Vested app. You can start investing in Grifols SA ADR (GRFS) with a minimum investment of $1.

How to invest in Grifols SA ADR shares from India?

You can invest in shares of Grifols SA ADR (GRFS) via Vested in three simple steps:

  • Click on Sign Up or Invest in GRFS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Grifols SA ADR shares
What is Grifols SA ADR 52-week high and low stock price?

The 52-week high price of Grifols SA ADR (GRFS) is $12.15. The 52-week low price of Grifols SA ADR (GRFS) is $5.3.

What is Grifols SA ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Grifols SA ADR (GRFS) is 35

What is Grifols SA ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Grifols SA ADR (GRFS) is 0.91

What is Grifols SA ADR dividend yield?

The dividend yield of Grifols SA ADR (GRFS) is 0.00%

What is the Market Cap of Grifols SA ADR?

The market capitalization of Grifols SA ADR (GRFS) is $7.13B

What is Grifols SA ADR’s stock symbol?

The stock symbol (or ticker) of Grifols SA ADR is GRFS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top